<DOC>
	<DOCNO>NCT02836925</DOCNO>
	<brief_summary>This non-randomized , single arm , phase II multicentre study sofosbuvir plus ledipasvir ± ribavirin ( genotype 1 , 3 4 ) sofosbuvir + ribavirin ( genotype 2 ) patient hepatitis C virus-associated indolent B-cell lymphoma ( HCV-RNA positive ) .</brief_summary>
	<brief_title>Sofosbuvir+Ledipasvir ±Ribavirin Sofosbuvir+Ribavirin Pts With Indolent Bcell Lymphoma Associated With HCV Infection Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin ( G1 , 3 4 ) Sofosbuvir+Ribavirin ( G2 ) Pts With Hepatitis C Virus Associated Indolent B-cell Lymphomas</brief_title>
	<detailed_description>The study include antiviral treatment interferon-free regimen follow lymphoma restaging ; follow end antiviral treatment patient evaluate sustained virological response safety parameter every 3 month 1 year every 6 month 2 year . ORR vital status also evaluate .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Indolent B cell lymphoma include : marginal zone lymphoma ( nodal , extranodal , splenic disseminate ) , lymphoplasmacytic lymphoma , small lymphocytic lymphoma , follicular lymphoma grade 1 2 , CD5‐negative B‐cell lymphoma NOS 3 . HCV‐RNA positivity 4 . Assessable HCV genotype 5 . No previous therapy lymphoma 6 . Measurable disease diagnostic biopsy ( long axis ≥1.5 cm nodal ≥1 cm extranodal lesion ) and/or evaluable disease ( quantifiable BM infiltrate ≥5 x 109/l clonal Bcell peripheral blood case exclusive BM/leukemic disease CD5negative Bcell lymphoma NOS ) 7 . No need immediate lymphoma treatment define absence follow criterion : systemic symptom , bulky nodal extranodal mass ( &gt; 7 cm ) , symptomatic splenomegaly , progressive leukemic phase , serous effusion 8 . Performance status &lt; 2 accord ECOG scale 9 . Adequate hematological count : ANC &gt; 1 x 109/L , hemoglobin &gt; 9 g/dl ( transfusion independent ) , platelet count &gt; 50 x 109/L ( transfusion independent ) 10 . No central nervous system ( CNS ) disease ( meningeal and/or brain involvement lymphoma ) 11 . Adequate kidney function ( creatinine clearance ≥ 45 ml/min ) 12 . Cardiac ejection fraction ≥45 % ( echocardiography MUGA scan ) 13 . Normal lung function 14 . Non peripheral neuropathy active neurological non neoplastic disease CNS 15 . Non major surgical intervention prior 3 month enrolment due lymphoma and/or disease life‐threatening compromise chemotherapy treatment 16 . Disease free prior malignancy lymphoma &gt; 3 year exception currently treat squamous cell basal cell carcinoma skin carcinoma situ cervix breast 17 . Life expectancy &gt; 6 month 18 . No psychiatric illness precludes understanding concept trial signing inform consent 19 . Written inform consent 20 . Women must : postmenopausal least 1 year ( must natural menses least 12 month ) surgically sterile ( hysterectomy bilateral oophorectomy , tubal ligation , otherwise incapable pregnancy ) , completely abstinent ( discretion investigator/per local regulation ) ( periodic abstinence intercourse permit ) sexually active , practice highly effective method birth control ( eg , prescription oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , double‐barrier method ( eg : condom , diaphragm , cervical cap , spermicidal foam , cream , gel , male partner sterilization ) local regulation permit , entry , must agree continue use method contraception throughout study . They must also prepared continue birth control measure least 6 month terminate treatment . 21 . Women childbearing potential must negative serum urine beta‐human chorionic gonadotropin ( betahCG ) pregnancy test screen 22 . Men must agree use acceptable method contraception ( female partner list ) duration study . Men must agree use double barrier method birth control donate sperm study 1 month receive last dose study drug take ribavirin 6 month receive last dose study drug take ribavirin . 1 . Diagnosis lymphoblastic lymphoma , Burkitt lymphoma , diffuse large Bcell lymphoma , mantle cell lymphoma , follicular lymphoma grade 3 , primary mediastinal Bcell lymphoma 2 . Previous antiHCV treatment sustain virological response 3 . Diagnosis cirrhosis ( histological Stiffness &gt; 12 KpA ) 4 . CNS disease ( meningeal and/or brain involvement lymphoma ) 5 . History clinically relevant liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , rheumatologic , hematologic , psychiatric , metabolic disturbance 6 . Uncontrolled diabetes ( receive antidiabetic agent , subject must stable dose least 3 month first dose study drug ) 7 . Concomitant therapy amiodarone 8 . Uncontrolled severe cardiovascular disease include myocardial infarction within six month enrollment , New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , 9 . Cardiac ejection fraction &lt; 45 % ( MUGA scan echocardiography ) . 10 . Creatinine clearance &lt; 45 ml/min 11 . Presence major neurological disorder 12 . HIV positivity , HBV positivity ( HbsAg+ HBVDNA+ ) exception HBcAb+ , HbsAg , HBsAb+/ patient HBVDNA negativity 13 . Ongoing systemic bacterial , fungal viral infection time initiation study treatment ( define require therapeutic dose antimicrobial , antifungal antiviral agent ) 14 . Major surgical intervention prior 3 month enrollment due lymphoma and/or 15 . Prior malignancy lymphoma last 3 year exception currently treat squamous cell basal cell carcinoma skin carcinoma situ cervix breast 16 . Life expectancy &lt; 6 month 17 . Any coexist medical psychological condition would preclude participation study compromise ability give inform consent . 18 . If female , patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>NHL</keyword>
	<keyword>Indolent B-cell lymphoma</keyword>
</DOC>